Top

Published in:

25-01-2024 | Metastasis | Peritoneal Surface Malignancy

Normal CEA Levels After Neoadjuvant Chemotherapy and Cytoreduction with Hyperthermic Intraperitoneal Chemoperfusion Predict Improved Survival from Colorectal Peritoneal Metastases

Authors: Michael M. Wach, MD, Geoffrey Nunns, MD, Ahmed Hamed, MD, Joshua Derby, MS, Mark Jelinek, MS, Curtis Tatsuoka, PhD, Matthew P. Holtzman, MD, Amer H. Zureikat, MD, David L. Bartlett, MD, Steven A. Ahrendt, MD, James F. Pingpank, MD, M. Haroon A. Choudry, MD, Melanie Ongchin, MD

Published in: Annals of Surgical Oncology | Issue 4/2024

Abstract

Background

Normal carcinoembryonic antigen (CEA) levels (≤ 2.5 ng/ml) after resection of localized colorectal cancer or liver metastases are associated with improved survival, however, these trends are understudied for colorectal peritoneal metastases (CRPM).

Patients and Methods

We conducted a retrospective single-institution study of patients with CRPM undergoing cytoreductive surgery with hyperthermic intraperitoneal chemoperfusion (CRS/HIPEC) with and without neoadjuvant chemotherapy (NACT). CEA was measured before and after NACT and within 3 months after CRS/HIPEC.

Results

A total of 253 patients (mean age 55.3 years) with CRPM undergoing CRS/HIPEC had complete CEA data and 191 also underwent NACT with complete data. The median peritoneal carcinomatosis index score (PCI) of the overall cohort was 12 and 82.7% of patients had complete cytoreduction (CC0). In total, 64 (33.5%) patients had normal CEA levels after NACT with a median overall survival (OS) of 45.2 months compared with those with an elevated CEA (26.4 months, p = 0.004). Patients with normal CEA after NACT had a lower PCI found at the time of surgery than those with elevated CEA (10 versus 14, p < 0.001), 68 (26.9%) patients with an elevated preoperative CEA level experienced normalization after CRS/HIPEC, and 118 (46.6%) patients had elevated CEA after CRS/HIPEC. Patients who experienced normalization demonstrated similar OS to patients that had normal CEA levels pre- and post-surgery and improved OS compared with those with elevated postop CEA (median 41.9 versus 47 months versus 17.1 months, respectively, p < 0.001).

Conclusions

Normal CEA levels after NACT and/or CRS/HIPEC are associated with improved survival for patients with CRPM. Patients that normalize CEA levels after surgery have similar survival to those with normal preoperative levels.

Available only for authorised users

Sanchez-Hidalgo JM, Rodriguez-Ortiz L, Arjona-Sanchez A, et al. Colorectal peritoneal metastases: optimal management review. World J Gastroenterol. 2019;25(27):3484–502.CrossRefPubMedPubMedCentral

Jayne DG, Fook S, Loi C, Seow-Choen F. Peritoneal carcinomatosis from colorectal cancer. Br J Surg. 2002;89(12):1545–50.CrossRefPubMed

Le VH, Thornblade L, Ituarte PHG, Lai LL, Melstrom KA. Metachronous peritoneal metastases following curative resection for colon cancer: Understanding risk factors and patterns of recurrence. J Surg Oncol. 2021;123(2):622–9.CrossRefPubMed

Sadeghi B, Arvieux C, Glehen O, et al. Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer. 2000;88(2):358–63.CrossRefPubMed

Verwaal VJ, Boot H, Aleman BM, van Tinteren H, Zoetmulder FA. Recurrences after peritoneal carcinomatosis of colorectal origin treated by cytoreduction and hyperthermic intraperitoneal chemotherapy: location, treatment, and outcome. Ann Surg Oncol. 2004;11(4):375–9. https://doi.org/10.1245/ASO.2004.08.014.CrossRefPubMed

Verwaal VJ, Bruin S, Boot H, van Slooten G, van Tinteren H. 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol. 2008;15(9):2426–32. https://doi.org/10.1245/s10434-008-9966-2.CrossRefPubMed

Goéré D, Malka D, Tzanis D, et al. Is there a possibility of a cure in patients with colorectal peritoneal carcinomatosis amenable to complete cytoreductive surgery and intraperitoneal chemotherapy? Ann Surg. 2013;257:1065–71.CrossRefPubMed

Goere D, Souadka A, Faron M, et al. Extent of colorectal peritoneal carcinomatosis: attempt to define a threshold above which HIPEC does not offer survival benefit: a comparative study. Ann Surg Oncol. 2015;22(9):2958–64. https://doi.org/10.1245/s10434-015-4387-5.CrossRefPubMed

Yang SY, Kang JH, Kim HS, Han YD, Min BS, Lee KY. Status of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with peritoneal carcinomatosis from colorectal cancer. J Gastrointest Oncol. 2019;10(6):1251–65.CrossRefPubMedPubMedCentral

10.

Quénet F, Elias D, Roca L, et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(2):256–66.CrossRefPubMed

11.

Simkens GA, Rovers KP, Nienhuijs SW, de Hingh IH. Patient selection for cytoreductive surgery and HIPEC for the treatment of peritoneal metastases from colorectal cancer. Cancer Manag Res. 2017;9:259–66.CrossRefPubMedPubMedCentral

12.

de Bree E, Koops W, Kroger R, van Ruth S, Witkamp AJ, Zoetmulder FA. Peritoneal carcinomatosis from colorectal or appendiceal origin: correlation of preoperative CT with intraoperative findings and evaluation of interobserver agreement. J Surg Oncol. 2004;86(2):64–73.CrossRefPubMed

13.

Hall C, Clarke L, Pal A, et al. A review of the role of carcinoembryonic antigen in clinical practice. Ann Coloproctol. 2019;35(6):294–305.CrossRefPubMedPubMedCentral

14.

Huo YR, Huang Y, Liauw W, Zhao J, Morris DL. Prognostic value of carcinoembryonic antigen (CEA), AFP, CA19-9 and CA125 for patients with colorectal cancer with peritoneal carcinomatosis treated by cytoreductive surgery and intraperitoneal chemotherapy. Anticancer Res. 2016;36(3):1041–9.PubMed

15.

Verberne CJ, Wiggers T, Grossmann I, de Bock GH, Vermeulen KM. Cost-effectiveness of a carcinoembryonic antigen (CEA) based follow-up programme for colorectal cancer (the CEA Watch trial). Colorectal Dis. 2016;18(3):O91–6.CrossRefPubMed

16.

Stremitzer S, Stift J, Graf A, et al. CEA change after neoadjuvant chemotherapy including bevacizumab and clinical outcome in patients undergoing liver resection for colorectal liver metastases. Ann Surg Oncol. 2015;22(4):1315–23. https://doi.org/10.1245/s10434-014-4158-8.CrossRefPubMed

17.

American Joint Committee on Cancer. Chapter 20—Colon and rectum. In: AJCC Cancer Staging Manual. 8th ed. New York, NY: Springer; 2017.

18.

NCCN Clinical Practice Guidelines in Oncology for Colon Cancer V1.2023. National Comprehensive Cancer Network, 2023. Accessed [June 15,2023].

19.

Huang CS, Chen CY, Huang LK, Wang WS, Yang SH. Prognostic value of postoperative serum carcinoembryonic antigen levels in colorectal cancer patients who smoke. PLoS ONE. 2020;15(6):e0233687.CrossRefPubMedPubMedCentral

20.

Yang Y, Xu M, Huang H, et al. Serum carcinoembryonic antigen elevation in benign lung diseases. Sci Rep. 2021;11(1):19044.CrossRefPubMedPubMedCentralADS

21.

Kozman MA, Fisher OM, Rebolledo BJ, et al. CEA to peritoneal carcinomatosis index (PCI) ratio is prognostic in patients with colorectal cancer peritoneal carcinomatosis undergoing cytoreduction surgery and intraperitoneal chemotherapy: a retrospective cohort study. J Surg Oncol. 2018;117(4):725–36.CrossRefPubMed

22.

Nakagoe T, Sawai T, Ayabe H, et al. Prognostic value of carcinoembryonic antigen (CEA) in tumor tissue of patients with colorectal cancer. Anticancer Res. 2001;21(4B):3031–6.PubMed

23.

Bajenova O, Chaika N, Tolkunova E, et al. Carcinoembryonic antigen promotes colorectal cancer progression by targeting adherens junction complexes. Exp Cell Res. 2014;324:115–23.CrossRefPubMed

24.

Liu H, D’Alesio M, AlMasri S, et al. No survival benefit with suboptimal CA19-9 response: defining effective neoadjuvant chemotherapy in resectable or borderline resectable pancreatic cancer. HPB (Oxford). 2023;25(5):521–32.CrossRefPubMed

25.

Jones RP, Pugh SA, Graham J, Primrose JN, Barriuso J. Circulating tumour DNA as a biomarker in resectable and irresectable stage IV colorectal cancer; a systematic review and meta-analysis. Eur J Cancer. 2021;144:368–81.CrossRefPubMed

26.

Beagan JJ, Sluiter NR, Bach S, et al. Circulating tumor DNA as a preoperative marker of recurrence in patients with peritoneal metastases of colorectal cancer: a clinical feasibility study. J Clin Med. 2020;9(6):1738.CrossRefPubMedPubMedCentral

27.

Sullivan BG, Lo A, Yu J, et al. Circulating tumor DNA is unreliable to detect somatic gene alterations in gastrointestinal peritoneal carcinomatosis. Ann Surg Oncol. 2023;30:278–84. https://doi.org/10.1245/s10434-022-12399-y.CrossRefPubMed

28.

Vallejos PA, Gonda A, Yu J, et al. Plasma exosome gene signature differentiates colon cancer from healthy controls. Ann Surg Oncol. 2023;30(6):3833–44. https://doi.org/10.1245/s10434-023-13219-7.CrossRefPubMedPubMedCentral

29.

Dhiman A, Kothary V, Witmer HDD, et al. Role of tumor-informed personalized ctdna assay in informing recurrence in patients with peritoneal metastases from colorectal and high-grade appendix cancer undergoing curative intent surgery. Ann Surg. 2023. doi: https://doi.org/10.1097/SLA.0000000000005856. Epub ahead of print.

Title: Normal CEA Levels After Neoadjuvant Chemotherapy and Cytoreduction with Hyperthermic Intraperitoneal Chemoperfusion Predict Improved Survival from Colorectal Peritoneal Metastases
Authors: Michael M. Wach, MD
Geoffrey Nunns, MD
Ahmed Hamed, MD
Joshua Derby, MS
Mark Jelinek, MS
Curtis Tatsuoka, PhD
Matthew P. Holtzman, MD
Amer H. Zureikat, MD
David L. Bartlett, MD
Steven A. Ahrendt, MD
James F. Pingpank, MD
M. Haroon A. Choudry, MD
Melanie Ongchin, MD
Publication date: 25-01-2024
Publisher: Springer International Publishing
Keywords: Metastasis
Colorectal Cancer
Colorectal Cancer
Peritoneal Cancer
Peritoneal Carcinomatosis
Cytostatic Therapy
Published in: Annals of Surgical Oncology / Issue 4/2024
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-024-14901-0

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Normal CEA Levels After Neoadjuvant Chemotherapy and Cytoreduction with Hyperthermic Intraperitoneal Chemoperfusion Predict Improved Survival from Colorectal Peritoneal Metastases

Abstract

Background

Patients and Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Patients and Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 4/2024

A Feasibility Randomized Controlled Trial of Prehabilitation During Neoadjuvant Chemotherapy for Women with Breast Cancer: A Mixed Methods Study

Early Complications in Prepectoral Tissue Expander-Based Breast Reconstruction

The Efficacy and Safety of an Indocyanine Green-Macroaggregated Albumin-Hyaluronic Acid Mixture (LuminoMark™) for Surgical Localization of Recurrent Thyroid Cancer

ASO Visual Abstract: Surgeon Perspectives on the Management of Aborted Cancer Surgery: Results of an SSO Member Survey

ASO Author Reflections: Does Wound VAC Temporization Offer Similar Patient-Reported Outcomes as Single-Stage Excision Reconstruction After Myxofibrosarcoma Resection?

Staying a Step Ahead: Tailoring Chemotherapy for Esophageal Cancer